Fluoxetine (Prozac) is one of the most widely prescribed pharmaceuticals, yet important aspects of its mechanism of action remain unknown. We previously reported that fluoxetine and related antidepressants induce nose muscle contraction of C. elegans. We also reported the identification and initial characterization of mutations in seven C. elegans genes that cause defects in this response (Nrf, nose resistant to fluoxetine). Here we present genetic evidence that the known nrf genes can be divided into two subgroups that confer sensitivity to fluoxetine-induced nose contraction by distinct pathways. Using both tissue-specific promoters and genetic mosaic analysis, we show that a gene from one of these classes, nrf-6, functions in the intestine to confer fluoxetine sensitivity. Finally, we molecularly identify nrf-5, another gene in the same class.
INTRODUCTION
Understanding the molecular mechanisms of action of drugs is essential for rational development and delivery of compounds with greater efficacy, greater specificity, and fewer adverse side effects. Genetic screens for mutants with altered responses to drugs constitute an approach to identifying drug mechanisms of action that is particularly promising for identifying novel targets and pathways (SCHAFER 1999) . Genetic screens using C. elegans have been successful in identifying drug targets. For example, screens for resistance to the antihelminthic drug levamisole led to the identification of levamisole-sensitive acetylcholine receptors (FLEMING et al. 1997; LEWIS et al. 1980) and screens for resistance to another antihelminthic drug, ivermectin, led to the identification of a novel class of ivermectin-sensitive glutamate-gated chloride channels (DENT et al. 2000) . In addition to identifying direct drug targets, genetic resistance screens can also identify components of signaling pathways that are affected by the drug of interest. For example, the acetylcholinesterase inhibitor aldicarb causes increased synaptic acetylcholine levels and aldicarb resistant mutants have identified several novel components of synaptic transmission (MILLER et al. 1996; 3 Fluoxetine resistance in C. elegans MILLER et al. 2000; NGUYEN et al. 1995) Finally, such screens can identify genes involved in drug metabolism, transport, or localization, which are key factors in determining in vivo drug availability and efficacy.
We isolated mutations affecting seven Nrf genes that cause resistance to nose contraction by the antidepressant fluoxetine (Nrf: nose resistant to fluoxetine). Genetic analysis suggested that three of these genes, nrf-5, nrf-6, and ndg-4, function in a common pathway, and that mutations in these genes confer their fluoxetine-resistant phenotype by a similar mechanism (CHOY and THOMAS 1999) . Here, we describe further genetic and molecular characterization of the Nrf genes. We construct double mutants between two classes of Nrf mutants and demonstrate that these two classes confer fluoxetine resistance by different pathways. We have examined the site of action of nrf-6 and found that it is required in the intestine for sensitivity to fluoxetine-induced nose contraction.
We have also cloned nrf-5 and found that it is homologous to a family of mammalian secreted lipid-binding proteins. A nrf-5::gfp fusion is expressed in the intestine, suggesting nrf-5 is secreted into the pseudocoelomic fluid where it could function in drug transport.
MATERIALS AND METHODS

Genetics and pharmacology:
General culturing and maintenance of strains was as described (BRENNER 1974) . For nrf (Peg); nrf (non-Peg) double mutants, the Peg mutation was followed by the Peg phenotype and the non-Peg mutation
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Fluoxetine resistance in C. elegans was balanced in trans with flanking double mutant chromosomes (Peg: pale eggs, CHOY and THOMAS 1999). To construct nrf-2; nrf-3 double mutants, both mutations were balanced in trans. All double mutants were confirmed by complementation testing. Nrf assays were performed as previously described (CHOY and THOMAS 1999) .
Mosaic analysis: nrf-6(sa367); lin-15(n756ts) mutants were injected with nrf-6 rescuing cosmid C08B11 (5 ng/µl), pbLH98 lin-15(+) (60 ng/µl) (CLARK et al. 1994 ) and pTJ1286 sur-5::gfp (100 ng/µl) (YOCHEM et al. 1998) to create the extrachromosomal array used for mosaic analysis. Animals that had lost the array completely were Peg due to nrf-6(sa367) and Muv (multivulva) due to lin-15(n765ts). Mosaic animals that lost the extrachromosomal array in the E lineage (intestine) were picked by their Peg and non-Muv phenotypes. Mosaic animals that lost the array in the AB lineage (hypodermis, including nose hypodermis, neurons, etc.) were picked by their non-Peg and partial Muv phenotypes.
Candidate mosaic animals were scored for GFP expression in the nose hypodermis and intestine using a dissecting microscope with a UV lamp attachment, and were then scored for the Nrf phenotype after incubation in 1.0 mg/ml fluoxetine for 10 minutes. The GFP expression pattern was then confirmed using a compound microscope with Nomarski optics and epifluorescence.
Molecular biology : nrf-5(sa513); lin-15(n756ts) animals were rescued for both the Nrf and Peg phenotypes by cosmid pools containing F55B12, by F55B12 alone, or by pRC28, a 4.5 kb subclone containing the predicted gene F55B12.5 and 1.8 kb of promoter. Bulk PCR products of F55B12.5 from wild-type and nrf-Fluoxetine resistance in C. elegans 5(sa513) genomic DNA were sequenced using an ABI automated sequencer and the sa513 mutation was confirmed by sequencing on both strands.
nrf-5 cDNAs yk56b12 and yk32e7 were obtained from the DNA Data Bank of Japan and were sequenced to confirm intron-exon boundaries of the F55B12.5
Genefinder predicted gene. From these sequences, we determined that an earlier prediction was missing a 75 bp intron in predicted exon 8 that was spliced out in both yk32e7 and yk56b12. In addition, we determined that exon 4 is spliced as predicted in both cDNAs. The yk32e7 cDNA is almost full length; it terminates 7 bp downstream of the predicted ATG of F55B12.5. Subsequent to our sequencing efforts, additional overlapping ESTs (yk1134g07, yk1436a01, yk1440f07, etc.) sequenced by the Genome Consortium and documented on WormBase (release WS138)confirmed that the F55B12.5 predicted ATG codon corresponds to the true translation initiation site of nrf-5. Both yk32e7 and yk56b12 have 89 nt 3' UTRs followed by a poly-A tail.
The nrf-5::gfp plasmid pRC34 was created by inserting the GFP coding region from pPD95.67 (A. FIRE) in a SnaBI site (generated by a silent mutation) at Val548 in nrf-5 rescuing plasmid pRC28 (see above). nrf-5(sa513); lin-15(n756ts) animals were injected with pRC34 (25 ng/µl), pbLH98 (60 ng/µl) and pBluescript (Stratagene, La Jolla, CA) (78 ng/µl, carrier), and transgenic lines were analyzed for rescue of nrf-5 and GFP expression. An intestinal-specific version of the nrf-6::gfp rescuing plasmid pRC17 (CHOY and THOMAS 1999) was made by deleting a 1 kb NotI-EcoR1 fragment of the promoter region followed by Klenow enzyme filling and religation.
RESULTS
Nrf-Nrf double mutants:
We previously found that Nrf mutants are only partially fluoxetine resistant (CHOY and THOMAS 1999) . One explanation for this observation is that they play similar roles in conferring sensitivity to fluoxetineinduced nose contraction, but act in parallel. If this were the case, then Nrf-Nrf double mutants should have increased resistance to fluoxetine-induced nose contraction when compared to the single mutants. Alternatively, the Nrf genes could act in a common signaling pathway. In this case, Nrf-Nrf double mutants should have similar resistance as single null mutants. In order to distinguish between these hypotheses, we constructed various Nrf-Nrf double mutants and assayed their response to fluoxetine.
We previously found that all pairwise combinations of double mutants between null alleles of the three Nrf Peg genes, nrf-5, nrf-6, and ndg-4, were indistinguishable from the respective single mutants for both the Nrf and Peg phenotypes (CHOY and THOMAS 1999) . These results suggest that nrf-5, nrf-6 and ndg-4 function in the same pathway to confer sensitivity to fluoxetine-induced nose contraction, and that elimination of the function of any of these three genes is sufficient to eliminate the function of the entire pathway. In order to test whether Nrf non-Peg genes nrf-2 and nrf-3 act in a common pathway, we constructed nrf-2; nrf-3 double mutants and assayed their Nrf phenotype. We found that the nrf-2; nrf-3 double mutant was slightly more resistant to fluoxetine 7 Fluoxetine resistance in C. elegans induced nose contraction than either of the single mutants ( Figure 1A ). Finally, to determine whether the Nrf Peg genes and the Nrf non-Peg genes act to confer fluoxetine sensitivity by different pathways, we constructed double mutants between these two classes. We constructed all pairwise combinations between Nrf Pegs nrf-5, nrf-6 and ndg-4 with Nrf non-Pegs nrf-2 and nrf-3 (with the exception of nrf-2 nrf-6, because these genes are closely linked to each other on chromosome II). We found that all these double mutants were much more resistant to fluoxetine than the respective single mutants ( (CHOY and THOMAS 1999) . Because the mutants were isolated for a phenotype that affects the nose muscles and the nrf-6 and ndg-4 hypodermal expression is highest in the hypodermal cells surrounding those muscles (hyp 4 and hyp 5), we hypothesized that expression of these genes in the nose hypodermal cells was required for fluoxetine-induced nose contraction. In contrast, the pale egg phenotype of nrf-6 and ndg-4 results from a defect in yolk protein transport. In C. elegans, yolk proteins are normally synthesized in the intestine, secreted into the pseudocoelomic space and then taken up into 8 Fluoxetine resistance in C. elegans oocytes prior to fertilization (GRANT and HIRSH 1999; KIMBLE and SHARROCK 1983) . nrf-6 and ndg-4 mutants accumulate yolk globules in the pseudocoelomic fluid, suggesting that yolk transport into oocytes, rather than yolk synthesis, is defective. However, this observation is also consistent with a defect in some aspect of yolk synthesis or transport from the intestine that decreases efficiency of yolk protein uptake into oocytes. It therefore seemed reasonable that nrf-6 and ndg-4 expression in the intestine is required for efficient yolk transport into oocytes.
We used mosaic analysis to determine the site of action of nrf-6 for each of the two nrf-6 mutant phenotypes. C. elegans extrachromosomal arrays are lost at a low frequency during mitosis and can therefore be used to generate mosaic animals (STINCHCOMB et al. 1985) . We expressed an extrachromosomal array composed of sur-5::gfp and a genomic cosmid containing nrf-6(+) in a nrf-6(sa367) mutant strain. sur-5::gfp is expressed in nearly every cell in C. elegans and can therefore be used as a cell-autonomous marker (YOCHEM et al., 1998) .
The intestinal and hypodermal cell types are conveniently separated in the C. elegans cell lineage: the nose hypodermal cells, including hyp 4 and hyp 5, are derived from the AB blastomere, whereas the intestinal cells are derived from the E blastomere (Figure 2 ; SULSTON et al., 1983) .
We identified 10 mosaic animals that had lost the extrachromosomal array in all intestinal cells but were still expressing GFP in most or all of the nose hypodermal cells hyp 4 and hyp 5 (see Materials and Methods). All 10 of these mosaics were both Nrf and Peg. We also isolated the reciprocal class of mosaic 9 Fluoxetine resistance in C. elegans animals that had lost the extrachromosomal array in nose hypodermal cells but not in the intestine. Nine out of 10 of these mosaics were non-Nrf and non-Peg (Figure 2 ). Taken together, the data from these two classes of mosaic animals indicate that, contrary to our expectations, nrf-6 expression is required in the intestine for fluoxetine-induced nose contraction as well as for efficient yolk transport. The significance of nrf-6 expression in the hypodermis remains unclear. We also performed additional experiments expressing nrf-6(+) under either an intestinal-specific truncated nrf-6 promoter or a hypodermal-specific dpy-7 promoter (GILLEARD et al. 1997 ) in nrf-6(sa367) mutants. We found that intestinal-specific expression of nrf-6(+) rescued both the Nrf and Peg defects of nrf-6 mutants, whereas hypodermal-specific expression did not rescue either of the defects (data not shown). The results of these tissue-specific expression experiments support the conclusions of our mosaic analysis. Although we did not perform mosaic analysis of ndg-4, nrf-6 and ndg-4 have identical mutant phenotypes and act in the same pathway by genetic criteria. Moreover, nrf-6 and ndg-4 encode homologous proteins and have the same expression pattern based on GFP fusions (CHOY and THOMAS 1999) . We conclude that ndg-4 very likely also acts in the intestine to confer sensitivity to fluoxetine-induced nose contraction and mediate efficient yolk uptake. mutants (see Materials and Methods). We sequenced F55B12.5 genomic DNA from nrf-5(sa513) mutants and found a stop mutation at Ser159 (Figure 3 ). This early stop mutation is predicted to be a null allele. Based on these results, we conclude that nrf-5 is F55B12.5. We obtained two nrf-5 EST cDNAs from the C.
elegans Genome Project and sequenced them to determine the intron-exon boundaries of F55B12.5 (see Materials and Methods). Using BLAST searches, we found that NRF-5 is homologous to four mammalian secreted lipid-binding proteins: bactericidal permeability increasing protein (BPI, BEAMER 2003; BEAMER et al. 1997; GRAY et al. 1989) , lipopolysaccharide binding protein (LBP, FENTON and GOLENBOCK 1998; IOVINE et al. 2002; MULERO et al. 2002) , cholesteryl ester transfer protein (CETP, BRUCE et al. 1998a; KAWANO et al. 2000) and phospholipid transfer protein (PLTP, HUUSKONEN et al. 1999; VAKKILAINEN et al. 2002) . These proteins have diverse functions, but share the ability to bind various lipids. NRF-5 is also similar to a number of predicted C. elegans proteins of unknown function (with corresponding orthologs in the related nematode C. briggsae) as well as several fish protein predictions (Figure 4) . Interestingly, no convincing reciprocal match to nrf-5 was found in the Drosophila genome. BPI and LBP both bind to lipopolysaccharide (LPS), a component of bacterial cell walls, and function in the immune system during bacterial infection (BEAMER et al. 1999; IOVINE et al. 2002; WEISS 2003) . CETP and PLTP are involved in metabolism and transport of cholesterol and other lipids in the bloodstream (BRUCE et al. 1998b; DESRUMAUX et al. 2001; KAWANO et al. 2000) . The only common function among members of this diverse family is the ability to bind to large hydrophobic molecules such as lipids and cholesterol (BRUCE et al. 1998a; GUYARD-DANGREMONT et al. 1999) .
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The structure of BPI at atomic resolution has been determined by X-ray crystallography (BEAMER et al. 1997) . One molecule of the phospholipid phosphatidyl choline was bound to BPI in each of two hydrophobic binding pockets. It was proposed that other phospholipids would be able to bind in this pocket as well, consistent with the relatively low specificity of lipid substrate binding among members of the family (BEAMER et al. 1997) . From the BPI crystal structure, 47 out of 456 amino acids were predicted to interact with the bound phospholipids. nrf-5 is 35% similar to BPI overall, but it is 53% similar among these 47 predicted lipid contact residues (Figure 3 ). This degree of conservation is similar to other family members such as CETP and PLTP (36% and 42% similar to BPI overall and 49% and 57% similar among lipid contact residues, respectively). Therefore, it is likely that nrf-5 binds large hydrophobic molecules in a similar binding pocket.
Models for nrf-5, nrf-6 and ndg-4 function: The Nrf Peg mutants nrf-5, nrf-6
and ndg-4 represent a specific subclass of the mutants isolated in a screen for Nrf mutants (CHOY and THOMAS 1999) . The nrf-6 and ndg-4 gene products, as with all members of this protein family, contain a consensus acyl transferase domain identified by Clusters of Orthologous Groups (COGs) analysis (National Center for Biotechnology Information). Interestingly, one Drosophila member of the NRF-6/NDG-4 family has been reported to be expressed in embryonic and adult nervous tissue (DZITOYEVA et al. 2003) . Based on the mutant phenotypes and molecular identities of the C. elegans genes, several models are possible to
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Fluoxetine resistance in C. elegans explain how nrf-5, nrf-6 and ndg-4 function in wild-type animals to confer sensitivity to fluoxetine-induced nose contraction and to mediate uptake of yolk proteins. We outline the details of two such models in the following sections. For example, several neurotransmitter receptors including nicotinic acetylcholine receptors and glutamate receptors have been shown to be modulated by the lipid composition of the membranes in which they are imbedded (GAGNE et al. 1996; SUNSHINE and MCNAMEE 1994) . Alternatively, changes in lipid composition could result in changes in lipid secondary messenger pools (GRABER et al. 1994; LEEVERS et al. 1999 ) in a signaling pathway that is responsible for fluoxetineinduced nose contraction. It is important to note that Nrf mutants do not have a non-specific decrease in nose muscle excitability because they are fully sensitive to several non-antidepressant drugs that induce muscle contraction (CHOY and THOMAS 1999) .
Although the suggestion that changes in lipid metabolism could result in neuromuscular defects is unusual, there are at least two precedents for similar mutant phenotypes. First, C. elegans fat-3 fatty acid desaturase mutants are defective in the biosynthesis of long chain polyunsaturated fatty acids and have uncoordinated movement defects (LESA et al. 2003; WATTS et al. 2003) . Second, Drosophila easily shocked mutants were isolated on the basis of a bang-sensitive paralytic phenotype, and easily shocked encodes an ethanolamine kinase, an enzyme involved in the biosynthesis of the ubiquitous phosphatidyl ethanolamine Fluoxetine resistance in C. elegans (PAVLIDIS et al. 1994 ). The exact mechanisms by which mutations in these two genes confer these mutant phenotypes have not yet been fully elucidated, but these examples clearly demonstrate that defects in lipid metabolism can result in unexpected neuromuscular defects and support the idea that the Nrf phenotype of nrf-5, nrf-6 and ndg-4 mutants could be explained by similar defects. 
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